Hence, it is important to note that BCL-2 is oncogenic and BCL-2 inhibitors experimentally reduce tumour growth [53], yet BCL-2 expression is associated with a favourable prognosis in MC due to its association with the ER+ subtype. The gene discussed is BCL2; the disease is neoplasm.